Associated tags: Biotechnology, Research, Health, Pharmaceutical, Medication, HKEX, Science, Antibody, Clinical Trials, Therapy, Vaccine, Pharmaceutical industry, General Health
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Medication,
KOSDAQ,
Partnership,
CNS,
Epitope,
CMC,
Quality of life,
ABL,
Antibody,
HKEX,
Therapy,
ADC Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
Key Points:
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
- Based on this platform, both companies will be able to discuss expanding their collaboration for various types of ADC development.
- Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased to collaborate with ABL, a company that possesses advanced platforms for cancer immunotherapy and treatments against CNS diseases.
- Together, we aim to expedite the development of innovative bsADC therapies.”
Sang Hoon Lee, CEO of ABL, said, “We are excited to establish this partnership with Biocytogen for bsADCs.
Oncology,
Health,
Neurology,
Genetics,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Medication,
KOSDAQ,
Partnership,
CNS,
Epitope,
Research,
CMC,
Quality of life,
ABL,
Antibody,
HKEX,
Therapy,
ADC Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
Key Points:
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
- Based on this platform, both companies will be able to discuss expanding their collaboration for various types of ADC development.
- Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased to collaborate with ABL, a company that possesses advanced platforms for cancer immunotherapy and treatments against CNS diseases.
- Together, we aim to expedite the development of innovative bsADC therapies.”
Sang Hoon Lee, CEO of ABL, said, “We are excited to establish this partnership with Biocytogen for bsADCs.
Retrieved on:
Tuesday, February 20, 2024
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Therapy,
Gilead Sciences,
Drug development,
Medication,
HKEX,
Antibody,
Pharmaceutical industry Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc.
Key Points:
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc.
- The agreement provides Gilead access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets.
- Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead’s evaluation of certain antibodies directed to a given nominated target.
- Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are thrilled to collaborate with Gilead, a partner renowned for their drug development and commercialization expertise.
Retrieved on:
Monday, February 19, 2024
Health,
Infectious Diseases,
Managed Care,
Research,
Science,
Pharmaceutical,
Biotechnology,
Therapy,
Gilead Sciences,
Drug development,
Medication,
HKEX,
Antibody,
Pharmaceutical industry Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc.
Key Points:
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc.
- The agreement provides Gilead access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets.
- Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead’s evaluation of certain antibodies directed to a given nominated target.
- Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are thrilled to collaborate with Gilead, a partner renowned for their drug development and commercialization expertise.
Retrieved on:
Wednesday, January 24, 2024
Research,
Infectious Diseases,
Neurology,
Cardiology,
Biotechnology,
Managed Care,
Pharmaceutical,
Health,
Science,
Oncology,
Hook effect,
DSM-IV codes,
Therapy,
Monoclonal antibody,
Merck Group,
ADC,
TCR,
TRACON,
HKEX,
Partnership,
Infection,
IND,
Neurocrine,
Medication,
Antibody,
Protein,
PCC,
Multinational corporation,
Hansoh Pharmaceutical,
Vaccine RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
Key Points:
- RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
- The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company’s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
- Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene.
- RenMice-derived fully human antibodies can be developed into novel therapies to treat numerous cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.
Retrieved on:
Tuesday, January 23, 2024
Science,
Biotechnology,
Research,
Pharmaceutical,
General Health,
Health,
Genetics,
Clinical Trials,
Hook effect,
DSM-IV codes,
Therapy,
Monoclonal antibody,
Merck Group,
ADC,
TCR,
Multimedia,
TRACON,
HKEX,
Partnership,
Infection,
IND,
Neurocrine,
Medication,
Antibody,
Protein,
PCC,
Multinational corporation,
Hansoh Pharmaceutical,
Vaccine RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
Key Points:
- RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
- The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company’s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
- RenMice®-derived fully human antibodies can be developed into novel therapies to treat numerous cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.
- Biocytogen offers licensing and flexible partnering models for its RenMice fully human antibody/TCR discovery platforms.
Oncology,
Health,
Research,
Pharmaceutical,
Science,
Biotechnology,
Non-small-cell lung cancer,
HER2,
Drug development,
Breast,
Medication,
Service provider,
MD,
Therapy,
Pharmaceutical industry Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. (“Radiance”), a biotechnology company specializing in developing next generation Antibody Drug Conjugates.
Key Points:
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. (“Radiance”), a biotechnology company specializing in developing next generation Antibody Drug Conjugates.
- The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) for therapeutic product development, manufacturing and commercialization for all human indications worldwide.
- In addition, Biocytogen has the right to collect the sharing of sublicensing fee, if any, between Radiance and third party.
- Dr. Yuelei Shen, President and CEO of Biocytogen, said: “We are excited to collaborate with Radiance, a strong team with extensive experience in drug development, to develop a leading proprietary fully human bispecfic antibody drug conjugate.
Retrieved on:
Wednesday, December 27, 2023
Science,
Biotechnology,
Research,
Pharmaceutical,
General Health,
Health,
Clinical Trials,
Other Health,
AACR,
Neoplasm,
Ovarian cancer,
Antibody,
TCR,
HKEX,
Medication,
WT1,
CTM,
Patient,
Acute myeloid leukemia,
Therapy,
Bone marrow,
Vaccine Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and CtM Biotech (Shanghai) Co., Ltd ("CtM Bio") today jointly announce that the development of a tri-specific T cell engager for an intracellular target achieved milestone progress.
Key Points:
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and CtM Biotech (Shanghai) Co., Ltd ("CtM Bio") today jointly announce that the development of a tri-specific T cell engager for an intracellular target achieved milestone progress.
- The incorporation of the T co-stimulatory signal for WT1-targeting T cell engager further gives it the best-in-class properties and first-in-class potential.
- Dr. Yuelei Shen, President and CEO of Biocytogen, said, “Our collaborative efforts with CtM Bio have progressed rapidly, resulting in the identification of novel immunotherapies targeting WT1.
- This rapid and effective development of multi-specific T cell engagers undoubtedly validates CtM Bio’s advanced T-cell engager technology, along with our expertise in discovering fully human TCR-mimic antibodies against intracellular targets.
Retrieved on:
Wednesday, December 20, 2023
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
Antibody,
Neurocrine Biosciences,
HKEX,
DSM-IV codes,
Patient,
Medication,
Drug development,
Doctor of Philosophy,
Vaccine Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that it has entered into an antibody evaluation and option agreement with Neurocrine Biosciences, Inc.
Key Points:
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that it has entered into an antibody evaluation and option agreement with Neurocrine Biosciences, Inc.
- The agreement grants Neurocrine Biosciences access to Biocytogen’s fully human antibodies against multiple specified targets, with an option to license selected antibodies for therapeutic product development, manufacturing and commercialization for all uses worldwide.
- Additional targets may be included under this agreement subject to mutual agreement.
- Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are pleased that our RenMice®-derived fully human antibodies received recognition from Neurocrine Biosciences, a world-leading neuroscience-focused biopharmaceutical company.
Retrieved on:
Wednesday, December 20, 2023
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
General Health,
Health,
Clinical Trials,
Antibody,
Neurocrine Biosciences,
HKEX,
DSM-IV codes,
Patient,
Medication,
Drug development,
Doctor of Philosophy,
Vaccine Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that it has entered into an antibody evaluation and option agreement with Neurocrine Biosciences, Inc.
Key Points:
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that it has entered into an antibody evaluation and option agreement with Neurocrine Biosciences, Inc.
- The agreement grants Neurocrine Biosciences access to Biocytogen’s fully human antibodies against multiple specified targets, with an option to license selected antibodies for therapeutic product development, manufacturing and commercialization for all uses worldwide.
- Additional targets may be included under this agreement subject to mutual agreement.
- Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are pleased that our RenMice®-derived fully human antibodies received recognition from Neurocrine Biosciences, a world-leading neuroscience-focused biopharmaceutical company.
